{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:26:28Z","timestamp":1790508388081,"version":"4.1.0"},"reference-count":221,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003968","name":"Iran National Science Foundation","doi-asserted-by":"publisher","award":["4026662"],"award-info":[{"award-number":["4026662"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.pharmr.2025.100110","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T02:55:18Z","timestamp":1765421718000},"page":"100110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["From physiopathology to treatment of familial hypercholesterolemia: Existing and emerging pharmacotherapies"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4367-3884","authenticated-orcid":false,"given":"Arrigo F.G.","family":"Cicero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mahjoubin-Tehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u017deljko","family":"Reiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali H.","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tannaz","family":"Jamialahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.pharmr.2025.100110_bib1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.5603\/KP.2016.0157","article-title":"2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"74","author":"Catapano","year":"2016","journal-title":"Kardiol Pol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/jamacardio.2023.5366","article-title":"Familial hypercholesterolemia variant and cardiovascular risk in individuals with elevated cholesterol","volume":"9","author":"Zhang","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100110_bib3","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.jacc.2021.09.004","article-title":"Familial hypercholesterolemia","volume":"78","author":"Brandts","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmr.2025.100110_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2019.05.017","article-title":"Risk of cardiovascular disease outcomes in primary care subjects with familial hypercholesterolaemia: A cohort study","volume":"287","author":"Iyen","year":"2019","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100110_bib5","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100110_bib6","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.3390\/ijms19113426","article-title":"Familial hypercholesterolemia: the most frequent cholesterol metabolism disorder caused disease","volume":"19","author":"Benito-Vicente","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100110_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2019.103831","article-title":"Familial hypercholesterolemia: a complex genetic disease with variable phenotypes","volume":"63","author":"Di Taranto","year":"2020","journal-title":"Eur J Med Genet"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MOL.0000000000000386","article-title":"Complexity of mechanisms among human proprotein convertase subtilisin\u2013kexin type 9 variants","volume":"28","author":"Dron","year":"2017","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100110_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1297\/cpe.30.201","article-title":"A case of autosomal recessive hypercholesterolemia with a novel mutation in the LDLRAP1 gene","volume":"30","author":"Nikasa","year":"2021","journal-title":"Clin Pediatr Endocrinol"},{"issue":"45","key":"10.1016\/j.pharmr.2025.100110_bib10","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100110_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jacl.2013.11.002","article-title":"Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy","volume":"8","author":"Vishwanath","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100110_bib13","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1161\/ATVBAHA.121.316862","article-title":"What is the prevalence of familial hypercholesterolemia?","volume":"41","author":"Brunham","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib14","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s11883-014-0482-5","article-title":"Familial hypercholesterolemia\u2014epidemiology, diagnosis, and screening","volume":"17","author":"Singh","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.pharmr.2025.100110_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijcard.2019.10.055","article-title":"Treatment of children with heterozygous familial hypercholesterolemia","volume":"304","author":"Reiner","year":"2020","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100110_bib16","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1177\/2047487318781360","article-title":"Treatment of children with homozygous familial hypercholesterolaemia","volume":"25","author":"Reiner","year":"2018","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100110_bib17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S2352-4642(21)00095-X","article-title":"Advances in familial hypercholesterolaemia in children","volume":"5","author":"Reijman","year":"2021","journal-title":"Lancet Child Adol Health"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100110_bib18","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100110_bib19","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/jpm11060464","article-title":"The prevalence of heterozygous familial hypercholesterolemia in selected regions of the Russian federation: The FH-ESSE-RF Study","volume":"11","author":"Meshkov","year":"2021","journal-title":"J Pers Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ijcard.2014.04.165","article-title":"Familial hypercholesterolemia in China: Prevalence and evidence of underdetection and undertreatment in a community population","volume":"174","author":"Shi","year":"2014","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib21","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1373\/clinchem.2014.231365","article-title":"Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries","volume":"61","author":"Futema","year":"2015","journal-title":"Clin Chem"},{"issue":"9874","key":"10.1016\/j.pharmr.2025.100110_bib22","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/jamacardio.2019.5173","article-title":"Reducing the clinical and public health burden of familial hypercholesterolemia: a global call to action","volume":"5","author":"Wilemon","year":"2020","journal-title":"JAMA Card"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100110_bib24","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrcardio.2015.92","article-title":"Management of patients with familial hypercholesterolaemia","volume":"12","author":"Reiner","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100110_bib25","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100110_bib26","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.3390\/jcm10214930","article-title":"Risk assessment and clinical management of children and adolescents with heterozygous familial hypercholesterolaemia. A position paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel","volume":"10","author":"Bjelakovic","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","article-title":"Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology","volume":"241","author":"De Backer","year":"2015","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib28","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41598-023-27963-z","article-title":"Women with familial hypercholesterolemia phenotype are undertreated and poorly controlled compared to men","volume":"13","author":"Zamora","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2025.100110_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.001","article-title":"Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration","volume":"22","author":"Vallejo-Vaz","year":"2016","journal-title":"Atherosclerosis Suppl"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.atherosclerosis.2015.09.021","article-title":"Familial hypercholesterolaemia: A global call to arms","volume":"243","author":"Vallejo-Vaz","year":"2015","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100110_bib31","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11883-023-01154-7","article-title":"Predictive modeling and structure analysis of genetic variants in familial hypercholesterolemia: implications for diagnosis and protein interaction studies","volume":"25","author":"Larrea-Sebal","year":"2023","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/joim.13577","article-title":"Genetic and molecular architecture of familial hypercholesterolemia","volume":"293","author":"Abifadel","year":"2023","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib33","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41598-020-58734-9","article-title":"Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR","volume":"10","author":"Galicia-Garcia","year":"2020","journal-title":"Sci Rep"},{"issue":"26","key":"10.1016\/j.pharmr.2025.100110_bib34","doi-asserted-by":"crossref","first-page":"13282","DOI":"10.1016\/S0021-9258(18)37702-0","article-title":"Mutational analysis of the ligand binding domain of the low density lipoprotein receptor","volume":"263","author":"Esser","year":"1988","journal-title":"J Biol Chem"},{"issue":"D1","key":"10.1016\/j.pharmr.2025.100110_bib35","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100110_bib37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.pharmr.2025.100110_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.06.971","article-title":"Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque","volume":"378","author":"Marfella","year":"2023","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100110_bib39","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc18-1491","article-title":"Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial","volume":"42","author":"Leiter","year":"2019","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100110_bib41","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100110_bib42","first-page":"462","article-title":"Factors associated with the presence of tendon xanthomas in familial hypercholesterolemia","volume":"77","author":"Corredoira","year":"2024","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (Engl Ed)"},{"issue":"13","key":"10.1016\/j.pharmr.2025.100110_bib43","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/eurheartj\/eht015","article-title":"Diagnosis and treatment of familial hypercholesterolaemia","volume":"34","author":"Hovingh","year":"2013","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100110_bib44","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jjcc.2020.07.005","article-title":"The value of physical signs in identifying patients with familial hypercholesterolemia in the era of genetic testing","volume":"76","author":"Rallidis","year":"2020","journal-title":"J Cardiol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00403-024-02863-y","article-title":"Examining treatment strategies for xanthelasma palpebrarum: a comprehensive literature review of contemporary modalities","volume":"316","author":"Yee","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib46","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2459\/JCM.0000000000001612","article-title":"Physical signs and atherosclerotic cardiovascular disease in familial hypercholesterolemia: the HELLAS-FH Registry","volume":"25","author":"Rallidis","year":"2024","journal-title":"J Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/3685265","article-title":"Premature valvular heart disease in homozygous familial hypercholesterolemia","volume":"2017","author":"Fahed","year":"2017","journal-title":"Cholesterol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib48","doi-asserted-by":"crossref","first-page":"634","DOI":"10.5551\/jat.42705","article-title":"Aortic root calcification score as an independent factor for predicting major adverse cardiac events in familial hypercholesterolemia","volume":"25","author":"Okada","year":"2018","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1743-7075-8-23","article-title":"Familial hypercholesterolemia: the lipids or the genes?","volume":"8","author":"Fahed","year":"2011","journal-title":"Nutr Metab (Lond)"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100110_bib52","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41569-019-0325-8","article-title":"Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care","volume":"17","author":"Watts","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib53","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/genes15030297","article-title":"Genetic counseling and genetic testing for familial hypercholesterolemia","volume":"15","author":"Tada","year":"2024","journal-title":"Genes (Basel)"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib54","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2015.07.020","article-title":"Cascade screening of familial hypercholesterolemia must go on","volume":"242","author":"Galema-Boers","year":"2015","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100110_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001795","article-title":"A comparison of the Netherlands, Norway and UK familial hypercholesterolemia screening programmes with implications for target setting and the UK\u2019s NHS long term plan","volume":"3","author":"Page","year":"2023","journal-title":"PLOS Glob Public Health"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100110_bib56","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40273-023-01347-7","article-title":"Cost-effectiveness of screening strategies for familial hypercholesterolaemia: an updated systematic review","volume":"42","author":"Marquina","year":"2024","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.pharmr.2025.100110_bib57","first-page":"4","article-title":"The time is now: achieving FH paediatric screening across Europe - The Prague Declaration","volume":"16","author":"Bedlington","year":"2022","journal-title":"GMS Health Innov Technol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib58","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacl.2023.11.001","article-title":"A systematic review of cost-effectiveness analysis of different screening strategies for familial hypercholesterolemia","volume":"18","author":"Meng","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/MED.0000000000000844","article-title":"Health economics of detection and treatment of children with familial hypercholesterolemia: to screen or not to screen is no longer the question","volume":"31","author":"Marquina","year":"2024","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2047487312460190","article-title":"Guidelines, position papers and critical reviews: differences and similarities","volume":"20","author":"Reiner","year":"2013","journal-title":"Eur J Prev Cardiol"},{"issue":"34","key":"10.1016\/j.pharmr.2025.100110_bib61","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmr.2025.100110_bib62","first-page":"190","article-title":"2025 Focused update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.pharmr.2025.100110_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol","volume":"73","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100110_bib64","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100110_bib65","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100110_bib66","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.clinthera.2013.06.019","article-title":"New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes","volume":"35","author":"Sahebkar","year":"2013","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100110_bib67","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10557-013-6479-4","article-title":"New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?","volume":"27","author":"Sahebkar","year":"2013","journal-title":"Cardiovasc Drugs Ther"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100110_bib68","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.3390\/jcm12185839","article-title":"Present and future of dyslipidaemia treatment\u2014a review","volume":"12","author":"Mer\u0107ep","year":"2023","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100110_bib69","first-page":"S26","article-title":"Medications for lipid control: statins vs newer drugs","volume":"40","author":"McPherson","year":"2024","journal-title":"Canad J Cardiol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib70","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/1043-6618(95)80042-5","article-title":"Pharmacology of competitive inhibitors of HMG-CoA reductase","volume":"31","author":"Corsini","year":"1995","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmr.2025.100110_bib71","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.phrs.2018.08.014","article-title":"Effect of statins on toll-like receptors: a new insight to pleiotropic effects","volume":"135","author":"Bahrami","year":"2018","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100110_bib72","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00204-023-03492-6","article-title":"Understanding the molecular mechanisms of statin pleiotropic effects","volume":"97","author":"German","year":"2023","journal-title":"Arch Toxicol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100110_bib73","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11745-010-3517-x","article-title":"Simvastatin therapy reduces prooxidant-antioxidant balance: Results of a placebo-controlled cross-over trial","volume":"46","author":"Parizadeh","year":"2011","journal-title":"Lipids"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib74","first-page":"546","article-title":"Association between statin use and plasma d-dimer levels: A systematic review and meta-analysis of randomised controlled trials","volume":"114","author":"Sahebkar","year":"2015","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib75","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1160\/th15-08-0620","article-title":"The impact of statin therapy on plasma levels of von Willebrand factor antigen: Systematic review and meta-analysis of randomised placebo-controlled trials","volume":"115","author":"Sahebkar","year":"2016","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/srep09902","article-title":"A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations","volume":"5","author":"Serban","year":"2015","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-020-00844-w","article-title":"Clinical pharmacology of statins: an update","volume":"22","author":"Ferri","year":"2020","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib78","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jjcc.2024.03.006","article-title":"Comprehensive review of statin-intolerance and the practical application of bempedoic acid. bempedoic acid","volume":"84","author":"Yarrarapu","year":"2024","journal-title":"J Cardiol"},{"key":"10.1016\/j.pharmr.2025.100110_bib79","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.phrs.2015.07.008","article-title":"Statin therapy and plasma coenzyme Q10 concentrations\u2014a systematic review and meta-analysis of placebo-controlled trials","volume":"99","author":"Banach","year":"2015","journal-title":"Pharmacol Res"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib80","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11926-024-01143-y","article-title":"Decoding the intricacies of statin-associated muscle symptoms","volume":"26","author":"Rastegar","year":"2024","journal-title":"Curr Rheumatol Rep"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100110_bib81","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2023.02.007","article-title":"Combination moderate-intensity statin and ezetimibe therapy for elderly patients with atherosclerosis","volume":"81","author":"Lee","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100110_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2024.0457","article-title":"Clinical efficacy of ezetimibe combined with rosuvastatin in the treatment of patients with primary hypercholesterolemia inadequately controlled by statin therapy","volume":"85","author":"Wei","year":"2024","journal-title":"Br J Hosp Med"},{"key":"10.1016\/j.pharmr.2025.100110_bib83","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin Pharmacokin"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib84","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2796.2008.02062.x","article-title":"Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials","volume":"265","author":"Pandor","year":"2009","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib85","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17425255.2018.1416094","article-title":"Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia","volume":"14","author":"Cicero","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.pharmr.2025.100110_bib86","article-title":"Efficacy and safety of statins, ezetimibe and statins-ezetimibe therapies for children and adolescents with heterozygous familial hypercholesterolaemia: Systematic review, pairwise and network meta-analyses of randomised controlled trials","volume":"401","author":"Llewellyn","year":"2024","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100110_bib87","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3390\/biomedicines13061460","article-title":"Reshaping dyslipidaemia treatment with bempedoic acid\u2014a narrative review","volume":"13","author":"Strikic","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib88","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/MOL.0000000000000911","article-title":"Bempedoic acid: new evidence and recommendations on use","volume":"35","author":"Paponja","year":"2024","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pharmr.2025.100110_bib89","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pcad.2023.03.001","article-title":"Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)","volume":"79","author":"Banach","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib91","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/14656566.2019.1583209","article-title":"ETC-1002 (bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials","volume":"20","author":"Ruscica","year":"2019","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100110_bib92","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2025.100110_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1028355","article-title":"Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome","volume":"9","author":"Biolo","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100110_bib94","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/17425255.2021.1951222","article-title":"Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia","volume":"17","author":"Cicero","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.pharmr.2025.100110_bib95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2022.03.020","article-title":"Long-term safety and efficacy of bempedoic acid in patients with atherosclerotic cardiovascular disease and\/or heterozygous familial hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)","volume":"174","author":"Ballantyne","year":"2022","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003121","article-title":"Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis","volume":"17","author":"Cicero","year":"2020","journal-title":"PLoS Med"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib97","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1016\/j.jacl.2023.12.005","article-title":"Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials","volume":"18","author":"Duell","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100110_bib98","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100110_bib99","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ehjcvp\/pvab064","article-title":"Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose\u2013response model","volume":"8","author":"Jadhav","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacl.2022.03.001","article-title":"Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials","volume":"16","author":"Laufs","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharmr.2025.100110_bib101","unstructured":"Nissen S, Lincoff A, Brennan D, et al. CLEAR outcomes investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 202(3):1353\u20131364."},{"issue":"8","key":"10.1016\/j.pharmr.2025.100110_bib102","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40264-020-00931-6","article-title":"Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies","volume":"43","author":"Cicero","year":"2020","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib103","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","article-title":"Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials","volume":"14","author":"Bays","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"10059","key":"10.1016\/j.pharmr.2025.100110_bib104","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib105","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2021.11.013","article-title":"Real-world utilization of bempedoic acid in an academic preventive cardiology practice","volume":"16","author":"Warden","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharmr.2025.100110_bib106","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.phrs.2017.03.023","article-title":"Regulation of PCSK9 by nutraceuticals","volume":"120","author":"Momtazi","year":"2017","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib107","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.drudis.2022.01.014","article-title":"Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia","volume":"27","author":"Ahamad","year":"2022","journal-title":"Drug Discov Today"},{"issue":"40","key":"10.1016\/j.pharmr.2025.100110_bib108","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1093\/eurheartj\/ehad566","article-title":"Third generation PCSK9-inhibitors","volume":"44","author":"Laufs","year":"2023","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.pharmr.2025.100110_bib109","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3390\/cells11192972","article-title":"PCSK9 inhibition: from current advances to evolving future","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib110","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100110_bib111","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/14712598.2017.1341485","article-title":"Emerging biologic therapies for hypercholesterolaemia","volume":"17","author":"Pucci","year":"2017","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100110_bib112","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1161\/JAHA.116.005367","article-title":"Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia","volume":"6","author":"Toth","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib113","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s11739-017-1708-7","article-title":"PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis","volume":"12","author":"Squizzato","year":"2017","journal-title":"Intern Emerg Med"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100110_bib114","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2174\/1570161118666200807114559","article-title":"PCSK9 Inhibitors and ezetimibe monotherapy in patients not receiving statins: a meta-analysis of randomized trials","volume":"19","author":"Benhuri","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40256-024-00682-0","article-title":"Efficacy of proprotein convertase subtilisin\/kexin type 9 inhibitors in patients with heterozygous familial hypercholesterolemia: a meta-analysis","volume":"25","author":"Movahedan","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9965","key":"10.1016\/j.pharmr.2025.100110_bib116","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib117","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jacc.2020.05.027","article-title":"Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial","volume":"76","author":"Blom","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmr.2025.100110_bib118","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2021.03.042","article-title":"A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia","volume":"325","author":"Brandts","year":"2021","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib119","first-page":"1308","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC: Cardiovasc Imaging"},{"issue":"18","key":"10.1016\/j.pharmr.2025.100110_bib120","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.pharmr.2025.100110_bib121","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100110_bib122","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","article-title":"Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE","volume":"147","author":"Gaba","year":"2023","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.pharmr.2025.100110_bib123","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100110_bib124","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.phrs.2019.03.021","article-title":"Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials","volume":"143","author":"Casula","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.pharmr.2025.100110_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1016802","article-title":"Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat","volume":"9","author":"Wang","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib126","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/eurjpc\/zwad332","article-title":"Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment","volume":"31","author":"Santos","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100110_bib127","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40272-024-00637-7","article-title":"Alirocumab: pediatric first approval","volume":"26","author":"Kang","year":"2024","journal-title":"Pediatr Drugs"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib128","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1161\/ATVBAHA.123.320268","article-title":"Evolocumab treatment in pediatric patients with homozygous familial hypercholesterolemia: pooled data from three open-label studies","volume":"44","author":"Raal","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib129","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14740338.2019.1620730","article-title":"Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data","volume":"18","author":"Strilchuk","year":"2019","journal-title":"Expert Opin Drug Saf"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100110_bib130","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMc1616623","article-title":"Antidrug antibodies in patients treated with alirocumab","volume":"376","author":"Roth","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib131","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States","volume":"6","author":"Heidenreich","year":"2013","journal-title":"Circ Heart Fail"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100110_bib132","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s11883-022-01074-y","article-title":"PCSK9 inhibition and risk of diabetes: should we worry?","volume":"24","author":"Carugo","year":"2022","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib133","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1056\/NEJMp1614154","article-title":"Oligonucleotide therapeutics\u2014a new class of cholesterol-lowering drugs","volume":"376","author":"Khvorova","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/8129513","article-title":"Advantages and disadvantages of inclisiran: a small interfering ribonucleic acid molecule targeting PCSK9\u2014a narrative review","volume":"2022","author":"Mer\u0107ep","year":"2022","journal-title":"Cardiovasc Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib135","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jacl.2022.06.009","article-title":"Small interfering ribonucleic acid for cholesterol lowering\u2013Inclisiran: Inclisiran for cholesterol lowering","volume":"16","author":"Soffer","year":"2022","journal-title":"J Clin Lipidol"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100110_bib136","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1111\/bph.15972","article-title":"Small interfering RNA: Discovery, pharmacology and clinical development\u2014An introductory review","volume":"180","author":"Ranasinghe","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib137","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/17460441.2024.2360415","article-title":"Inclisiran: the preclinical discovery and development of a novel therapy for the treatment of atherosclerosis","volume":"19","author":"Tsamoulis","year":"2024","journal-title":"Expert Opin Drug Discov"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib138","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2022.01.001","article-title":"Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment","volume":"16","author":"Kallend","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharmr.2025.100110_bib139","article-title":"Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies","volume":"13","author":"Cicero","year":"2022","journal-title":"Am Heart J Plus"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib141","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1097\/MS9.0000000000002982","article-title":"Efficacy and outcomes of inclisiran in the management of homozygous and heterozygous familial hypercholesterolemia: a systematic review and meta-analysis","volume":"87","author":"Khan","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib142","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib143","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/CIRCRESAHA.116.304637","article-title":"Contemporary aspects of the biology and therapeutic regulation of the microsomal triglyceride transfer protein","volume":"116","author":"Hooper","year":"2015","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib144","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/clp.13.74","article-title":"Lomitapide: a novel drug for homozygous familial hypercholesterolemia","volume":"9","author":"Panno","year":"2014","journal-title":"Clin Lipidol"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100110_bib145","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14656566.2017.1340941","article-title":"Lomitapide for the treatment of hypercholesterolemia","volume":"18","author":"Berberich","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharmr.2025.100110_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.937750","article-title":"Efficacy of long-term treatment of autosomal recessive hypercholesterolemia with lomitapide: a subanalysis of the Pan-European Lomitapide Study","volume":"13","author":"D\u2019Erasmo","year":"2022","journal-title":"Front Genet"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib147","doi-asserted-by":"crossref","first-page":"878","DOI":"10.5551\/jat.34777","article-title":"MTP gene variants and response to lomitapide in patients with homozygous familial hypercholesterolemia","volume":"23","author":"Kolovou","year":"2016","journal-title":"J Atheroscler Thromb"},{"issue":"12","key":"10.1016\/j.pharmr.2025.100110_bib148","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S2213-8587(24)00233-X","article-title":"Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study","volume":"12","author":"Masana","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib149","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s11033-024-10003-y","article-title":"Lomitapide: navigating cardiovascular challenges with innovative therapies","volume":"51","author":"Munkhsaikhan","year":"2024","journal-title":"Mol Biol Rep"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/phar.1351","article-title":"Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia","volume":"34","author":"Tuteja","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100110_bib151","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","article-title":"Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: Five-year data from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)","volume":"14","author":"Underberg","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100110_bib152","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11883-020-00858-4","article-title":"Lomitapide\u2013a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia","volume":"22","author":"Stefanutti","year":"2020","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100110_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.04.075","article-title":"The Lomitapide Observational Worldwide Evaluation Registry (LOWER) - Nine-year Effectiveness and Safety Data in HoFH","volume":"18","author":"Underberg","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharmr.2025.100110_bib154","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/011871529X305291240715112812","article-title":"Circumventing cardiovascular calamities: the dawn of ANGPTL3 blockade in severe dyslipidemia management","volume":"24","author":"Namitokov","year":"2024","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib155","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1194\/jlr.M054890","article-title":"ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys","volume":"56","author":"Gusarova","year":"2015","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmr.2025.100110_bib156","series-title":"Evinacumab therapy for homozygous familial hypercholesterolemia: driving lipoprotein clearance via the road less taken","author":"Toth","year":"2023"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib157","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2025.100110_bib158","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2021.04.014","article-title":"Marked plaque regression in homozygous familial hypercholesterolemia","volume":"327","author":"Reeskamp","year":"2021","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib159","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100110_bib160","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib161","article-title":"Atherosclerotic plaque regression in homozygous familial hypercholesterolaemia: a case report of a long-term lipid-lowering therapy involving LDL-receptor-independent mechanisms","volume":"7","author":"Khoury","year":"2023","journal-title":"Eur Heart J Case Rep"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100110_bib162","first-page":"1258","article-title":"Decreased LDL-cholesterol exposure following ANGPTL3 inhibition reduces coronary plaque development in homozygous familial hypercholesterolemia","volume":"17","author":"Schonck","year":"2024","journal-title":"JACC: Cardiovasc Imaging"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100110_bib163","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3390\/ph15111389","article-title":"Long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia: real-world clinical experience","volume":"15","author":"Stefanutti","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100110_bib164","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamacardio.2023.2921","article-title":"Longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia","volume":"8","author":"Rosenson","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib165","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pharmr.2025.100110_bib166","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib167","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","article-title":"Evinacumab for pediatric patients with homozygous familial hypercholesterolemia","volume":"149","author":"Wiegman","year":"2024","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100110_bib168","doi-asserted-by":"crossref","first-page":"15513","DOI":"10.1021\/acs.jmedchem.2c01290","article-title":"Recent update on the development of PCSK9 inhibitors for hypercholesterolemia treatment","volume":"65","author":"Ahamad","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2025.100110_bib169","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside","volume":"9","author":"Bao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12916-023-02797-8","article-title":"Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)","volume":"21","author":"Chai","year":"2023","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib171","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40256-024-00654-4","article-title":"The efficacy of tafolecimab in Chinese patients with hypercholesterolemia: a systematic review and meta-analysis","volume":"24","author":"Fatima","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib172","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1097\/MS9.0000000000001945","article-title":"Hypercholesterolemia: a literature review on management using tafolecimab: a novel member of PCSK9 monoclonal antibodies","volume":"86","author":"Qureshi","year":"2024","journal-title":"Ann Med Surg"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100110_bib173","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s40265-023-01952-y","article-title":"Tafolecimab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.pharmr.2025.100110_bib174","first-page":"1","article-title":"Ebronucimab: first approval","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.pharmr.2025.100110_bib175","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107340","article-title":"Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab","volume":"207","author":"Zhang","year":"2024","journal-title":"Pharmacol Res"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100110_bib176","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40265-025-02199-5","article-title":"Recaticimab: first approval","volume":"85","author":"Lamb","year":"2025","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.pharmr.2025.100110_bib177","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.jacc.2024.07.035","article-title":"Recaticimab monotherapy for nonfamilial hypercholesterolemia and mixed hyperlipemia: the phase 3 REMAIN-1 randomized trial","volume":"84","author":"Xu","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100110_bib178","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.numecd.2024.04.011","article-title":"Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia","volume":"34","author":"Zhao","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100110_bib179","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033669","article-title":"Efficacy and safety of ongericimab in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia","volume":"13","author":"Wang","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pharmr.2025.100110_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119120","article-title":"Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"403","author":"Lin","year":"2025","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib181","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/acsptsci.3c00256","article-title":"Model-informed dose selection for a novel human immunoglobulin G4 derived monoclonal antibody targeting proprotein convertase kwashiorkor type 9: insights from population pharmacokinetics\u2013pharmacodynamics and systems pharmacology","volume":"7","author":"Peng","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100110_bib182","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.amjcard.2017.02.020","article-title":"Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the Phase 2 EQUATOR Study)","volume":"119","author":"Baruch","year":"2017","journal-title":"Am J Cardiol"},{"issue":"17","key":"10.1016\/j.pharmr.2025.100110_bib183","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/eurheartj\/ehv707","article-title":"Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study","volume":"37","author":"Kastelein","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib184","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cts.12430","article-title":"A phase I randomized study of a specifically engineered, pH-sensitive PCSK9 inhibitor RN317 (PF-05335810) in hypercholesterolemic subjects on statin therapy","volume":"10","author":"Levisetti","year":"2017","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib185","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","article-title":"Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor","volume":"148","author":"Johns","year":"2023","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100110_bib186","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib187","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S2213-8587(23)00325-X","article-title":"PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial","volume":"12","author":"Koren","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"10.1016\/j.pharmr.2025.100110_bib188","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","article-title":"An oral PCSK9 inhibitor for treatment of hypercholesterolemia: the PURSUIT randomized trial","volume":"85","author":"Koren","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl_3","key":"10.1016\/j.pharmr.2025.100110_bib189","doi-asserted-by":"crossref","first-page":"12579","DOI":"10.1161\/circ.142.suppl_3.12579","article-title":"Abstract 12579: CVI-LM001, a first-in-class novel oral PCSK9 modulator, lowers plasma Ldl-c and reduces circulating PCSK9 in preclinical animal models and in hyperlipidemic human subjects","volume":"142","author":"Liu","year":"2020","journal-title":"Circulation"},{"issue":"40","key":"10.1016\/j.pharmr.2025.100110_bib190","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","article-title":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial","volume":"44","author":"Raal","year":"2023","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100110_bib191","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jamacardio.2024.1659","article-title":"Efficacy and Safety of lerodalcibep in patients with or at high risk of cardiovascular disease: a randomized clinical trial","volume":"9","author":"Klug","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib192","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S2213-8587(24)00313-9","article-title":"Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial","volume":"13","author":"Raal","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100110_bib193","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00228-021-03149-2","article-title":"A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9","volume":"77","author":"Zeitlinger","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100497","article-title":"VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys","volume":"65","author":"Vroom","year":"2024","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmr.2025.100110_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115960","article-title":"Novel ASO therapeutic target designed against hyperlipidemia via PCSK9 knockdown","volume":"170","author":"Yu","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib196","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4161\/rna.6.3.8807","article-title":"Locked nucleic acid as a novel class of therapeutic agents","volume":"6","author":"Veedu","year":"2009","journal-title":"RNA Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib197","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: A new era of lipid lowering therapy","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J Cardiol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib198","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.pharmr.2025.100110_bib199","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1111\/bcp.15425","article-title":"AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval","volume":"88","author":"Reki\u0107","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2025.100110_bib200","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ehjcvp\/pvad103","article-title":"VERVE-101: a promising CRISPR-based gene editing therapy that reduces LDL-C and PCSK9 levels in HeFH patients","volume":"10","author":"Horie","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"10489","key":"10.1016\/j.pharmr.2025.100110_bib201","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/S0140-6736(25)00507-0","article-title":"Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"405","author":"Ray","year":"2025","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib202","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.cmet.2022.03.006","article-title":"Identification and evaluation of a lipid-lowering small compound in preclinical models and in a phase I trial","volume":"34","author":"Wang","year":"2022","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2025.100110_bib203","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35869-4","article-title":"Engineering of a GLP-1 analogue peptide\/anti-PCSK9 antibody fusion for type 2 diabetes treatment","volume":"8","author":"Chodorge","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib204","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00125-018-4789-6","article-title":"Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus","volume":"62","author":"Jain","year":"2019","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.pharmr.2025.100110_bib205","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.drudis.2021.03.016","article-title":"Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: An update","volume":"26","author":"Banerjee","year":"2021","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib206","first-page":"152","article-title":"Cholesteryl ester transfer protein inhibitors and cardiovascular outcomes: a systematic review and meta-analysis","volume":"11","author":"Rehman Wu","year":"2024","journal-title":"J Cardiovasc Dev Dis"},{"issue":"16","key":"10.1016\/j.pharmr.2025.100110_bib207","doi-asserted-by":"crossref","first-page":"9417","DOI":"10.3390\/ijms23169417","article-title":"Cholesteryl ester transfer protein inhibition reduces major adverse cardiovascular events by lowering apolipoprotein B levels","volume":"23","author":"Nelson","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10.1016\/j.pharmr.2025.100110_bib208","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","article-title":"Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?","volume":"118","author":"Nurmohamed","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100110_bib209","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/jcph.2448","article-title":"Guiding dyslipidemia treatment: a population pharmacokinetic\u2013pharmacodynamic framework for obicetrapib","volume":"64","author":"Dunn","year":"2024","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2025.100110_bib210","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.pharmr.2025.100110_bib211","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.5551\/jat.64828","article-title":"Obicetrapib as an adjunct to stable statin therapy in Japanese subjects: results from a randomized phase 2 trial","volume":"31","author":"Harada-Shiba","year":"2024","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100110_bib212","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","article-title":"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial","volume":"17","author":"Ballantyne","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib213","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jacl.2024.12.016","article-title":"Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis","volume":"19","author":"Masson","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.pharmr.2025.100110_bib214","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ahj.2024.05.002","article-title":"Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN","volume":"274","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.pharmr.2025.100110_bib215","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MOL.0000000000000839","article-title":"Lipoprotein (a) in familial hypercholesterolaemia","volume":"33","author":"Durrington","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pharmr.2025.100110_bib216","first-page":"371","article-title":"Variants in LPA are associated with familial hypercholesterolaemia: whole genome sequencing analysis in the 100 000 Genomes Project","author":"Bird","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"10.1016\/j.pharmr.2025.100110_bib217","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jacl.2019.06.011","article-title":"Individuals with familial hypercholesterolemia and cardiovascular events have higher circulating Lp(a) levels","volume":"13","author":"Pavanello","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.pharmr.2025.100110_bib218","doi-asserted-by":"crossref","first-page":"234","DOI":"10.5603\/EP.a2023.0036","article-title":"Impact of alirocumab\/evolocumab on lipoprotein (a) concentrations in patients with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized controlled trials","volume":"74","author":"Dai","year":"2023","journal-title":"Endokrynol Pol"},{"issue":"9","key":"10.1016\/j.pharmr.2025.100110_bib219","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14254","article-title":"New insights into the therapeutic options to lower lipoprotein(a)","volume":"54","author":"Baragetti","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.pharmr.2025.100110_bib220","article-title":"Emerging Lp(a)-Lowering therapies: Is muvalaplin a potential breakthrough?","volume":"21","author":"Afzal","year":"2024","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"issue":"23","key":"10.1016\/j.pharmr.2025.100110_bib221","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran\u2014A small-interfering RNA targeting lipoprotein(a)","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725075192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699725075192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:19:51Z","timestamp":1774433991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699725075192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":221,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0031699725075192"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100110","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From physiopathology to treatment of familial hypercholesterolemia: Existing and emerging pharmacotherapies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2025.100110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100110"}}